The use of tranexamic acid (TXA) has markedly increased since the results of the CRASH-II trial were published. In addition to its use in trauma, TXA has been evaluated and used in numerous other conditions, including post-partum hemorrhage and epistaxis. Recently, the HALT-IT Trial was published online in the Lancet, which evaluated the use of TXA in patients with acute gastrointestinal bleeding. In this podcast we discuss the HALT-IT Trial and its implications for clinical practice.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
With increasing water temperatures, there is a rise in the incidence of V.vulnificus infections in non-endemic regions. Patients with V.vulnificus infection are often critically...
ED Pharmacist extraordinaire Jill Logan joins CCPEM to discuss the use of high-dose nitroglycerin in patients with acute cardiogenic pulmonary edema. Is it safe? ...
Over 500,000 patients suffer sudden cardiac arrest each year in the United States. Though survival rates are improving, there remains significant variation in outcomes...
